




## Supplemental Figure 1



### Supplemental Figure 1 Legend

LAPC4 cells were treated as in Figure 2. Top: mTOR inhibitor administration concurrent with IR (Schedule I). Middle: mTOR inhibitors administered as neoadjuvant to IR (Schedule II). Bottom: mTOR inhibitors administered as adjuvant to IR (Schedule III).